Fractyl Health is a metabolic therapeutics company developing disease-modifying treatments for type 2 diabetes and obesity. Its lead platform, the Revita DMR System, is an outpatient endoscopic procedure that uses hydrothermal ablation to resurface the duodenal mucosa and reset the metabolic signalling associated with chronic high-fat, high-sugar diets; the company reported six-month topline results from the 308-patient randomized, double-blind, sham-controlled REMAIN-1 Pivotal Cohort in October 2026, and is pursuing Revita as a weight-maintenance therapy after GLP-1 discontinuation. Its second platform, Rejuva, is an adeno-associated virus-delivered pancreatic gene therapy designed to restore endogenous metabolic hormone function for durable remission of type 2 diabetes and obesity. Founded as Fractyl Laboratories in 2010 and renamed Fractyl Health in June 2021, the company is headquartered in Burlington, Massachusetts and completed its initial public offering on Nasdaq in February 2024 at $15.00 per share.
Fractyl Health disclosed in an SEC Form 8-K (Item 2.05) a ~45% workforce reduction (~45 of ~100 employees) and discontinued internal development of its Rejuva AAV pancreatic gene therapy program to cut quarterly cash burn by 50% and focus exclusively on an FDA De Novo marketing submission for its Revita DMR post-GLP-1 weight maintenance procedure.
Burlington, Massachusetts-based Fractyl Health is laying off approximately 45% of its staff (~45 roles) and discontinuing internal development of its Rejuva pancreatic gene therapy program to focus resources on an FDA De Novo marketing submission for its Revita post-GLP-1 weight maintenance procedure.
Co-Founder, Chief Executive Officer and Director
Co-Founder, President and Chief Product Officer
Chief Financial Officer
No active job listings. Check back later.